Back

Dr. Bryan Finkle

Dr. Bryan Finkle, Sports Medicine Research & Testing Laboratory

Schedule

Dr. Bryan S. Finkle is a consultant in pre-clinical new drug development and medico-legal toxicology. For ten years, 1973-1983, Dr. Finkle was the Director of the Center for Human Toxicology at the University of Utah, and from 1983-1989 was Director of the Department of Pharmacological Sciences at Genentech, Inc. South San Francisco, California. During this period he was Associate Professor of Pharmacology-Toxicology in the College of Pharmacy, and Department of Pathology in the College of Medicine, University of Utah Health Sciences Center. Until 1996, Dr. Finkle was the Vice President for Development and Regulatory Affairs at Canji, Inc., a biotechnology company dedicated to gene therapy using tumor suppressor genes, novel cancer therapeutics and diagnostics. From 2000-02 he was associated with NewBiotics Inc., a biotechnology company dedicated to the development of enzyme catalyzed therapeutic agents. He continues to consult for medical biotechnology companies, particularly Ligocyte Pharmaceuticals concerning the development of recombinant vaccines. He is educated in chemistry, pharmacology and toxicology and began his career in forensic science at the Scotland Yard laboratory in England (1956), specializing in toxicology. In 1964, he was appointed Chief Forensic Toxicologist in Santa Clara County in San Jose, California and later lectured in forensic toxicology at the University of California, School of Criminology at Berkeley. He is currently Chief Consulting Toxicologist to the National Football League, and consultant to the World and U.S. Anti-doping Agencies. He is the President and Chairman of the Board for the Sports Medicine Research and Testing Laboratory Inc. He serves on the Board of the NFL Health Foundation; the Scientific Advisory Board of the Partnership for Clean Competition, and consults with the NFL-NFLPA Research and Education Foundation. Dr. Finkle has been consultant to FDA, NIDA, (SAMHSA) and other government and private agencies involved with the toxicology of drug abuse. He has consulted with major pharmaceutical companies on toxicology and pre-clinical pharmacology of new drugs, most recently in development of products from biotechnology research. He is Past President of the International Association of Forensic Toxicologists and of the Forensic Sciences Foundation, Past Vice-President of the American Academy of Forensic Sciences and a member of several states, national and international organizations of forensic scientists and toxicologists. He has also served on Pharmaceutical Manufacturer’s Association committees, and a National Academy of Sciences-National Research Council Study Committee. For 50 years he has been closely associated with research into the problems of alcohol and drugs, their toxicology and their role in medico-legal investigation. For the past 20 years, he has also been involved in the toxicology and pre-clinical development of drugs (human proteins, peptides, biochemical mimetics, and genes) produced by recombinant DNA techniques. He directed the pre-clinical pharmacology and toxicology of Protropin (human growth hormone) Activase (rec-tissue plasminogen activator) Interferon-gamma, Tumor Necrosis Factor-alpha, the Her-2 oncogene antibody and, most recently, the p53 and Rb human tumor suppressor genes. His main professional interests are in the study of instrumental, automated analytical methods; mass spectrometry as a tool in toxicology; and studies and experiments to provide a database for interpretation of toxicology data. He has published more than 100 papers in the scientific literature, numerous abstracts and published in books concerned with analytical, forensic and clinical toxicology; and safety assessment of bio-technology products. He has been featured in several international television and radio programs concerning forensic science and toxicology. He is recipient of the Stas Medal, awarded by the German Society of Toxicology and Chemistry and the Rolla Harger Award, an honor given by the American Academy of Forensic Sciences, Toxicology Section. In the fall of 1995 he received the Borkenstein Award from the National Safety Council for his more than 25 years of work on the role of alcohol and other drugs related to highway safety. Until 2013 Dr. Finkle’s avocation was the management of his horse and cattle ranch in the Madison Valley, Southwest Montana. At Finmans Mountain Ranch he bred, trained, competed and sold quality registered Quarter horse-cutting horses. A parallel but complementary activity involved breeding, training, and showing Arabian horses throughout the western states. He served for nine years on the Board of Directors of the Madison Valley Hospital and Clinic, and the Hospital Foundation. He was Chairman of the Board for the Montana Mandolin Society (2000-06)

Speakers